Physician profile
Sam Q Peng
NPI 1841221769
$9,502.63
in general payments reported to CMS, 2019-2025
47 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $1,358 · 2021: $2,476 · 2022: $1,741 · 2023: $677 · 2024: $801 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,090.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,366.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $769.79 | 2019-2025 | |
| Novo Nordisk INC | $689.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $652.43 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $649.26 | 2019-2025 | |
| Amgen INC. | $468.98 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $444.44 | 2019-2023 | |
| Astellas Pharma US INC | $336.45 | 2019-2025 | Veozah |
| Emd Serono, INC. | $278.61 | 2021-2024 | Mavenclad, Mavenclad |
| Bayer Healthcare Pharmaceuticals INC. | $270.65 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.88 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $257.06 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $254.12 | 2021 | |
| Jazz Pharmaceuticals INC. | $206.47 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $187.79 | 2020-2023 | Ajovy |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.